118 related articles for article (PubMed ID: 38717141)
1. On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity.
Edgar RCS; Malcolm TR; Siddiqui G; Giannangelo C; Counihan NA; Challis M; Duffy S; Chowdhury M; Marfurt J; Dans M; Wirjanata G; Noviyanti R; Daware K; Suraweera CD; Price RN; Wittlin S; Avery VM; Drinkwater N; Charman SA; Creek DJ; de Koning-Ward TF; Scammells PJ; McGowan S
mBio; 2024 Jun; 15(6):e0096624. PubMed ID: 38717141
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.
Deniskin R; Frame IJ; Sosa Y; Akabas MH
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473
[TBL] [Abstract][Full Text] [Related]
3. Genetic and chemical validation of
Edgar RCS; Siddiqui G; Hjerrild K; Malcolm TR; Vinh NB; Webb CT; Holmes C; MacRaild CA; Chernih HC; Suen WW; Counihan NA; Creek DJ; Scammells PJ; McGowan S; de Koning-Ward TF
Elife; 2022 Sep; 11():. PubMed ID: 36097817
[TBL] [Abstract][Full Text] [Related]
4. Local emergence in Amazonia of
Mathieu LC; Cox H; Early AM; Mok S; Lazrek Y; Paquet JC; Ade MP; Lucchi NW; Grant Q; Udhayakumar V; Alexandre JS; Demar M; Ringwald P; Neafsey DE; Fidock DA; Musset L
Elife; 2020 May; 9():. PubMed ID: 32394893
[TBL] [Abstract][Full Text] [Related]
5. Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.
Drinkwater N; Vinh NB; Mistry SN; Bamert RS; Ruggeri C; Holleran JP; Loganathan S; Paiardini A; Charman SA; Powell AK; Avery VM; McGowan S; Scammells PJ
Eur J Med Chem; 2016 Mar; 110():43-64. PubMed ID: 26807544
[TBL] [Abstract][Full Text] [Related]
6. Retargeting azithromycin analogues to have dual-modality antimalarial activity.
Burns AL; Sleebs BE; Siddiqui G; De Paoli AE; Anderson D; Liffner B; Harvey R; Beeson JG; Creek DJ; Goodman CD; McFadden GI; Wilson DW
BMC Biol; 2020 Sep; 18(1):133. PubMed ID: 32993629
[TBL] [Abstract][Full Text] [Related]
7. A New Thienopyrimidinone Chemotype Shows Multistage Activity against Plasmodium falciparum, Including Artemisinin-Resistant Parasites.
Bosson-Vanga H; Primas N; Franetich JF; Lavazec C; Gomez L; Ashraf K; Tefit M; Soulard V; Dereuddre-Bosquet N; Le Grand R; Donnette M; Mustière R; Amanzougaghene N; Tajeri S; Suzanne P; Malzert-Fréon A; Rault S; Vanelle P; Hutter S; Cohen A; Snounou G; Roques P; Azas N; Lagardère P; Lisowski V; Masurier N; Nguyen M; Paloque L; Benoit-Vical F; Verhaeghe P; Mazier D
Microbiol Spectr; 2021 Oct; 9(2):e0027421. PubMed ID: 34724729
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.
Le Bihan A; de Kanter R; Angulo-Barturen I; Binkert C; Boss C; Brun R; Brunner R; Buchmann S; Burrows J; Dechering KJ; Delves M; Ewerling S; Ferrer S; Fischli C; Gamo-Benito FJ; Gnädig NF; Heidmann B; Jiménez-Díaz MB; Leroy D; Martínez MS; Meyer S; Moehrle JJ; Ng CL; Noviyanti R; Ruecker A; Sanz LM; Sauerwein RW; Scheurer C; Schleiferboeck S; Sinden R; Snyder C; Straimer J; Wirjanata G; Marfurt J; Price RN; Weller T; Fischli W; Fidock DA; Clozel M; Wittlin S
PLoS Med; 2016 Oct; 13(10):e1002138. PubMed ID: 27701420
[TBL] [Abstract][Full Text] [Related]
9. Plasmodium falciparum Resistance to a Lead Benzoxaborole Due to Blocked Compound Activation and Altered Ubiquitination or Sumoylation.
Sindhe KMV; Wu W; Legac J; Zhang YK; Easom EE; Cooper RA; Plattner JJ; Freund YR; DeRisi JL; Rosenthal PJ
mBio; 2020 Jan; 11(1):. PubMed ID: 31992618
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Two-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitors.
Mistry SN; Drinkwater N; Ruggeri C; Sivaraman KK; Loganathan S; Fletcher S; Drag M; Paiardini A; Avery VM; Scammells PJ; McGowan S
J Med Chem; 2014 Nov; 57(21):9168-83. PubMed ID: 25299353
[TBL] [Abstract][Full Text] [Related]
12. A Variant PfCRT Isoform Can Contribute to
Dhingra SK; Redhi D; Combrinck JM; Yeo T; Okombo J; Henrich PP; Cowell AN; Gupta P; Stegman ML; Hoke JM; Cooper RA; Winzeler E; Mok S; Egan TJ; Fidock DA
mBio; 2017 May; 8(3):. PubMed ID: 28487425
[TBL] [Abstract][Full Text] [Related]
13. Examining Plasmodium falciparum and P. vivax clearance subsequent to antimalarial drug treatment in the Myanmar-China border area based on quantitative real-time polymerase chain reaction.
Lo E; Nguyen J; Oo W; Hemming-Schroeder E; Zhou G; Yang Z; Cui L; Yan G
BMC Infect Dis; 2016 Apr; 16():154. PubMed ID: 27084511
[TBL] [Abstract][Full Text] [Related]
14. Structural analyses of the malaria parasite aminoacyl-tRNA synthetases provide new avenues for antimalarial drug discovery.
Chhibber-Goel J; Yogavel M; Sharma A
Protein Sci; 2021 Sep; 30(9):1793-1803. PubMed ID: 34184352
[TBL] [Abstract][Full Text] [Related]
15. Plasmodium berghei K13 Mutations Mediate
Simwela NV; Stokes BH; Aghabi D; Bogyo M; Fidock DA; Waters AP
mBio; 2020 Nov; 11(6):. PubMed ID: 33173001
[TBL] [Abstract][Full Text] [Related]
16. Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
Vinh NB; Drinkwater N; Malcolm TR; Kassiou M; Lucantoni L; Grin PM; Butler GS; Duffy S; Overall CM; Avery VM; Scammells PJ; McGowan S
J Med Chem; 2019 Jan; 62(2):622-640. PubMed ID: 30537832
[TBL] [Abstract][Full Text] [Related]
17. Mapping the substrate specificity of the Plasmodium M1 and M17 aminopeptidases.
Malcolm TR; Swiderska KW; Hayes BK; Webb CT; Drag M; Drinkwater N; McGowan S
Biochem J; 2021 Jul; 478(13):2697-2713. PubMed ID: 34133730
[TBL] [Abstract][Full Text] [Related]
18. Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases.
McGowan S; Oellig CA; Birru WA; Caradoc-Davies TT; Stack CM; Lowther J; Skinner-Adams T; Mucha A; Kafarski P; Grembecka J; Trenholme KR; Buckle AM; Gardiner DL; Dalton JP; Whisstock JC
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2449-54. PubMed ID: 20133789
[TBL] [Abstract][Full Text] [Related]
19. Structure-based development of potent Plasmodium falciparum M1 and M17 aminopeptidase selective and dual inhibitors via S1'-region optimisation.
Calic PPS; Vinh NB; Webb CT; Malcolm TR; Ngo A; Lowes K; Drinkwater N; McGowan S; Scammells PJ
Eur J Med Chem; 2023 Feb; 248():115051. PubMed ID: 36634455
[TBL] [Abstract][Full Text] [Related]
20. KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
González-Bacerio J; Maluf SEC; Méndez Y; Pascual I; Florent I; Melo PMS; Budu A; Ferreira JC; Moreno E; Carmona AK; Rivera DG; Alonso Del Rivero M; Gazarini ML
Bioorg Med Chem; 2017 Sep; 25(17):4628-4636. PubMed ID: 28728898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
